In a meta-analysis [43] of 55 RCTs, treatment with SGLT-2 inhibitors was significantly associated with weight loss in patients with T2DM when compared with that with placebo, and a dose-dependent response in body weight reduction to dapagliflozin was observed. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.